Emerging Treatments for Erectile Dysfunction: a Review of Novel, Non-surgical Options
- 126 Downloads
Purpose of Review
To review novel, non-surgical therapies for erectile dysfunction (ED).
Recently, a landmark study identified the SIM1 locus, involved in the leptin-melanocortin pathway, as an independent risk factor for ED and a potential target for novel therapies. The recent literature otherwise has focused on low-intensity shock wave therapy (LiSWT), with several randomized trials and meta-analyses suggesting therapeutic efficacy.
There are few novel oral agents for ED. There is growing evidence suggesting efficacy of intracavernosal stem cells therapy and low-intensity shock wave therapy (LiSWT), although these therapies are still investigational. A better understanding of the pathophysiologic spectrum of ED will offer new opportunities for novel, non-surgical therapies for ED.
KeywordsErectile dysfunction Sexual dysfunction Physiological Dietary supplement Platelet-rich plasma Genetic therapy Extracorporeal shockwave therapy
Compliance with Ethical Standards
Conflict of Interest
Darshan P. Patel declares no potential conflicts of interest.
Alexander W. Pastuszak reports advisor, speaker, consultant, and research and fellowship support from Endo Pharmaceuticals; is an advisor for Boston Scientific and Antares Pharmaceuticals; and holds a leadership position with Woven Health.
James M. Hotaling reports a research and fellowship grant from Endo Pharmaceuticals and a fellowship grant from Boston Scientific; and holds leadership positions with Nanonc, SteamDx, and Andro360.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.Bohm M, Baumhakel M, Teo K, Sleight P, Probstfield J, Gao P, et al. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND). Trials Circulation. 2010;121(12):1439–46.PubMedCrossRefGoogle Scholar
- 8.Batty GD, Li Q, Czernichow S, Neal B, Zoungas S, Huxley R, et al. Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial. J Am Coll Cardiol. 2010;56(23):1908–13.PubMedPubMedCentralCrossRefGoogle Scholar
- 10.•• Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423–32 This recent guideline provides a comprehensive review of the evaluation and treatment of testosterone deficiency.PubMedCrossRefGoogle Scholar
- 16.Cowart M, Latshaw SP, Bhatia P, Daanen JF, Rohde J, Nelson SL, et al. Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. J Med Chem. 2004;47(15):3853–64.PubMedCrossRefGoogle Scholar
- 18.•• Jorgenson E, Matharu N, Palmer MR, Yin J, Shan J, Hoffmann TJ, et al. Genetic variation in the SIM1 locus is associated with erectile dysfunction. Proc Natl Acad Sci U S A. 2018;115(43):11018–23 This recent landmark study identified a genetic association between a SIM1 locus and ED. This genome-wide association study provides targets for other gene discoveries and novel ED therapies.PubMedPubMedCentralCrossRefGoogle Scholar
- 19.Albersen M, Linsen L, Tinel H, Sandner P, Van Renterghem K. Synergistic effects of BAY 60-4552 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure. J Sex Med. 2013;10(5):1268–77.PubMedCrossRefGoogle Scholar
- 29.•• Gu X, Hua S, Ethan M, Zhong L, Long T, Clouse C, et al. Long-term therapeutic effect of cell therapy on improvement in erectile function in a rat model with pelvic neurovascular injury. BJU international. 2018. This recent study demonstrates therapeutic efficacy of intracavernosal stem cell injection in an animal model. Normal saline (control), umbilical vein endothelial cells, adipose-derived stem cells, and amniotic fluid-derived stem cells were injected into the corpus cavernosum of rats. The authors show a significant increase in the intracavernosal pressure/mean arterial pressure ratio in treated rats compared with controls.Google Scholar
- 37.•• Campbell JD, Trock BJ, Oppenheim AR, Anusionwu I, Gor RA, Burnett AL. Meta-analysis of randomized controlled trials that assess the efficacy of low-intensity shockwave therapy for the treatment of erectile dysfunction. Ther Adv Urol. 2019;11:1756287219838364 This recent meta-analysis of randomized trials suggests therapeutic efficacy of LiSWT for ED.PubMedPubMedCentralCrossRefGoogle Scholar
- 44.Hesseler MJ, Shyam N. Platelet-rich plasma and its utility in medical dermatology - a systematic review. J Am Acad Dermatol. 2019.Google Scholar